153 related articles for article (PubMed ID: 9481570)
1. Ki 67 expression in 35 borderline ovarian tumours: relations with clinicopathologic parameters and ploidy.
Darai E; Walker-Combrouze F; Dauge-Geoffroy MC; Vincent Y; Feldmann G; Madelenat P; Scoazec JY
Eur J Obstet Gynecol Reprod Biol; 1998 Feb; 76(2):175-80. PubMed ID: 9481570
[TBL] [Abstract][Full Text] [Related]
2. Proliferating cell nuclear antigen (PCNA) and Ki-67 in epithelial ovarian tumours: correlation with DNA flow cytometric analysis.
Karaburun S; Karaveli S; Peştereli HE; Simsek T; Sargin CF
Adv Clin Path; 2001 Jan; 5(1-2):3-9. PubMed ID: 11753828
[TBL] [Abstract][Full Text] [Related]
3. Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features.
Huettner PC; Weinberg DS; Lage JM
Am J Pathol; 1992 Sep; 141(3):699-706. PubMed ID: 1381562
[TBL] [Abstract][Full Text] [Related]
4. DNA ploidy analysis of borderline epithelial ovarian tumours.
Lodhi S; Najam S; Pervez S
J Pak Med Assoc; 2000 Oct; 50(10):349-51. PubMed ID: 11109755
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers.
Henriksen R; Strang P; Backstrom T; Wilander E; Tribukait B; Oberg K
Anticancer Res; 1994; 14(2B):603-8. PubMed ID: 8010717
[TBL] [Abstract][Full Text] [Related]
6. Brenner tumours of the ovary: a study of the histology, immunohistochemistry and cellular DNA content in benign, borderline and malignant ovarian tumours.
Trebeck CE; Friedlander ML; Russell P; Baird PJ
Pathology; 1987 Jul; 19(3):241-6. PubMed ID: 3324024
[TBL] [Abstract][Full Text] [Related]
7. Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers.
Pujol JL; Simony J; Jolimoy G; Jaffuel D; Demoly P; Quantin X; Marty-Ané C; Boher JM; Charpentier R; Michel FB
Br J Cancer; 1996 Sep; 74(6):964-70. PubMed ID: 8826867
[TBL] [Abstract][Full Text] [Related]
8. Analysis of CD44 expression in serous and mucinous borderline tumours of the ovary: comparison with cystadenomas and overt carcinomas.
Darai E; Walker-Combrouze F; Fauconnier A; Madelenat P; Potet F; Scoazec JY
Histopathology; 1998 Feb; 32(2):151-9. PubMed ID: 9543672
[TBL] [Abstract][Full Text] [Related]
9. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
[TBL] [Abstract][Full Text] [Related]
10. DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors.
Kühn W; Kaufmann M; Feichter GE; Rummel HH; Schmid H; Heberling D
Gynecol Oncol; 1989 Jun; 33(3):360-7. PubMed ID: 2722063
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
12. Application of new ploidy-related parameters for the diagnosis of ovarian tumours.
Korabiowska M; Brinck U; Skubis J; Sattler B; Fischer G
Anticancer Res; 2004; 24(6):4191-4. PubMed ID: 15736472
[TBL] [Abstract][Full Text] [Related]
13. DNA ploidy and MYC DNA amplification in ovarian carcinomas. Correlation with p53 and bcl-2 expression, proliferative activity and prognosis.
Diebold J; Suchy B; Baretton GB; Blasenbreu S; Meier W; Schmidt M; Rabes H; Löhrs U
Virchows Arch; 1996 Nov; 429(4-5):221-7. PubMed ID: 8972757
[TBL] [Abstract][Full Text] [Related]
14. Numerical chromosomal aberrations in borderline, benign, and malignant epithelial tumors of the ovary: correlation with p53 protein overexpression and Ki-67.
Kohlberger PD; Kieback DG; Mian C; Wiener H; Kainz C; Gitsch G; Breitenecker G
J Soc Gynecol Investig; 1997; 4(5):262-4. PubMed ID: 9360232
[TBL] [Abstract][Full Text] [Related]
15. DNA ploidy of ovarian and adnexal cyst fluid. A useful adjunct to cytology.
Greenebaum E; Yee HT; Liu J
Acta Cytol; 1994; 38(2):201-8. PubMed ID: 8147211
[TBL] [Abstract][Full Text] [Related]
16. Hormonal activity of epithelial ovarian tumours in post-menopausal women.
Heinonen PK; Mörsky P; Aine R; Koivula T; Pystynen P
Maturitas; 1988 Mar; 9(4):325-38. PubMed ID: 3380017
[TBL] [Abstract][Full Text] [Related]
17. Study of borderline and invasive mucinous ovarian tumors using Ki-67 (MIB 1) antibodies and nucleolar organizer region (NOR) staining.
Terlikowski S; Sulkowski S; Lenczewski A; Musiatowicz B; Kulikowski M
Arch Gynecol Obstet; 1999 Nov; 263(1-2):29-33. PubMed ID: 10728625
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric analysis of nuclear DNA content in ovarian tumors. Association of ploidy with tumor type, histologic grade, and clinical stage.
Lage JM; Weinberg DS; Huettner PC; Mark SD
Cancer; 1992 Jun; 69(11):2668-75. PubMed ID: 1571896
[TBL] [Abstract][Full Text] [Related]
19. [DNA ploidy and results of first line chemotherapy in ovarian cancer patients].
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Debniak J
Ginekol Pol; 2006 Aug; 77(8):589-96. PubMed ID: 17076189
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma.
Victorzon M; Roberts PJ; Haglund C; von Boguslawsky K; Nordling S
Oncology; 1996; 53(3):182-91. PubMed ID: 8643219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
